Higher SARS-COV-2 spike antibody levels are associated with reduced risk of subsequent symptomatic and severe COVID-19. Jin, Yue; Yang, Fei; Rank, Christopher; Letovsky, Stanley; Ramge, Peter and Jochum, Simon from Roche Information Solutions, Roche Diagnostics GmbH, Roche Diagnostics Solutions, and Roche Diagnostics International presented a poster during ISPOR 2024. The objective was to assess the…

Creating a holistic direct to consumer (DTC) and healthcare provider (HCP) marketing strategy from scratch is a demanding task, especially if you don’t have the clinical expertise to precisely identify the consumers or providers you should be targeting. We’re here to give you 5 simple steps to creating a holistic DTC and HCP targeting strategy…

The healthcare analytics company partnered with Experian, DeepIntent, InsightsRx, and Comscore to deliver scale, precision, privacy-conscious targeting, and real-time measurement for pharmaceutical advertisers. PurpleLab®, the healthcare analytics company powering evidence-based decisions across life sciences, has announced a series of major partnerships with Experian, DeepIntent, InsightsRx, and Comscore. Together, these collaborations allow advertisers to use data…

Partnership introduces smarter, real-time HCP and DTC optimization leveraging PurpleLab®’s data and InsightsRx’s proprietary algorithmic intelligence. InsightsRx, a healthcare media company on a mission to transform real-world data into smarter, outcome-driven marketing, teams up with PurpleLab, a healthcare analytics company on a mission to make healthcare speak a single unified language to drive better outcomes….

Pharmaceutical brands and media platforms, including connected TV (CTV), can activate HIPAA-compliant audiences built on real-world clinical and claims data through a new collaboration between PurpleLab® and Experian. Targeting de-identified audiences is essential for engaging the right patients at pivotal moments in their health journey—maximizing ROI while safeguarding privacy and improving outcomes. Overall, prescription drugmakers…

Healthcare advertising works best when it’s both precise and efficient. That’s why we’re excited to announce a direct partnership with DeepIntent, bringing our high-quality audiences into the DeepIntent Audience Marketplace. This integration gives marketers faster, easier access to PurpleLab’s audiences, delivering better performance, greater scale, and sharper precision within a seamless workflow. For advertisers, that…

The collaboration extends PurpleLab®’s healthcare audience reach through Comscore’s AI predictive technology.   PurpleLab, a healthcare analytics company powering evidence-based decisions across life sciences, is now part of Comscore’s AI-powered Data Partner Network. The initiative enables data providers like PurpleLab to transform ID-based datasets into scalable, privacy-centric audiences using Proximic by Comscore’s proprietary AI predictive…

PurpleLab®, a healthcare analytics company specializing in real-world data, announced it has acquired KAID Health, an AI-powered clinical analytics and care management company. The combination brings together PurpleLab’s large-scale structured claims data with KAID Health’s artificial intelligence and natural language processing technology, creating a more complete view of patient journeys across structured and unstructured data…

Clinical trials are designed to evaluate the safety and efficacy of new therapies or medical devices. During these trials, evidence is gathered to determine if the asset is safe for patients, providing the intended benefit at the appropriate dosage, as well as identifying and minimizing any potential side effects.

Change is the only constant in digital advertising—and the upcoming retirement of Microsoft’s Xandr DSP is a perfect example of this volatility. For many pharma marketers and agencies, this shift isn’t just another platform update; it’s a critical juncture that could reshape how you reach your audiences and drive ROI. So, what happens when a…

In pharmaceutical development, where most therapies never reach the market, early and strategic data investments can make all the difference.